The strong Phase 1a data for ATI-052 de-risks the program and supports rapid advancement into Phase 2b. Traders should watch for Phase 1b POC results in AD and asthma in 2H 2026, which will be key catalysts. The selection of lichen planus for ATI-2138 opens a large, unaddressed market with no approved therapies, representing a significant upside opportunity.
Price Chart
Executive Summary
Aclaris reported positive full Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4R bispecific antibody, showing a favorable safety profile, an estimated half-life of ~45 days supporting up to every-three-month dosing, and complete/sustained inhibition of CCL17. The company also selected lichen planus as the lead Phase 2b indication for ATI-2138, an oral ITK/JAK3 inhibitor, with a basket study expected to initiate in 2H 2026. No financial data was reported.
Key Facts
- ATI-052 Phase 1a SAD/MAD results showed an estimated half-life of approximately 45 days, supporting potential for up to every-three-month dosing.
- ATI-052 demonstrated complete and sustained inhibition of ex vivo TSLP-stimulated CCL17 through at least week 20 and IL-4-stimulated CCL17 through at least week 12 in the 480 mg MAD cohort.
- ATI-052 was well tolerated with no SAEs, no Grade 3 drug-related TEAEs, and no conjunctivitis across all cohorts.
- Phase 1b POC trials in atopic dermatitis and asthma are enrolling and dosing, with top-line results expected in 2H 2026.
- Phase 2b program for ATI-052 initially targeting asthma to initiate in 4Q 2026.
- ATI-2138 selected lichen planus as lead Phase 2b indication; phased multi-part basket study to initiate in 2H 2026.
- Company estimates peak U.S. revenue potential for an oral LP therapeutic at $1B to $4B.
- No anti-drug antibody impact on PK or PD was observed.
- ATI-052 demonstrated 4.3x greater potency than the combination of dupilumab and tezepelumab in an in vitro assay.
Financial Impact
No financial results reported; company estimates peak U.S. revenue potential for ATI-2138 in lichen planus at $1B to $4B.
Risk Factors
- Phase 1b POC results in AD and asthma may not replicate the robust preclinical and Phase 1a data.
- ATI-2138 has not yet been tested in lichen planus patients; clinical failure risk remains.
- Company has no approved products and is pre-revenue; relies on financing for operations.
- Competitive landscape includes established biologics (dupilumab, tezepelumab) and emerging bispecifics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-049733 |
| Document: acrs-20260428x8k.htm | 0001104659-26-049733 |
| Document: acrs-20260428xex99d2.htm | 0001104659-26-049733 |
| Document: 0001104659-26-049733-index-headers.html | 0001104659-26-049733 |
| Document: 0001104659-26-049733-index.html | 0001104659-26-049733 |
| Document: 0001104659-26-049733.txt | 0001104659-26-049733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.79 (−35.10%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.79 (−37.77%) |
Apr 28, 2026 25w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 28, 2026 25w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.79 (−16.70%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.79 (+7.67%) |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | $3.79 (+2.71%) |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | $3.79 (+3.55%) |
Mar 11, 2026 32w ago | 8-K | $3.51 $3.74 | ▲ +6.55% | ▲ +7.53% | $3.79 (+7.98%) |
Feb 28, 2026 34w ago | Institutional Cluster | $3.05 $3.39 | ▲ +11.15% | ▲ +12.36% | $3.79 (+24.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers